---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-076728"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2024-09-09T23:59:59+00:00"
generated_at: "2026-05-31T05:56:52.908240+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics files 1-for-30 reverse stock split, reduces authorized shares to 250M

## Summary
- Stockholders approved 1-for-30 reverse split at Sept 3 annual meeting; effective Sept 11, 2024.
- Authorized common shares reduced from 750M to 250M via Sixth Certificate of Amendment.
- Board also amended 2021 Equity Plan to increase shares reserved from ~2.2M to ~10.6M (pre-split).
- Directors Gerald W. McLaughlin and Laura E. Benjamin re-elected to Class II.
- Trading symbol ALLR unchanged; no fractional shares, rounding up.

## SEC filing metadata
- accession: 0001213900-24-076728
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2024-09-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.03, 5.03, 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390024076728/0001213900-24-076728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390024076728/ea0213202-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-076728
- JSON: https://secwatch.observer/filing/0001213900-24-076728.json
- Plain text: https://secwatch.observer/filing/0001213900-24-076728.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.